Skip to main content
OpenTrials
Completed

NCT Number: NCT05825560

Opioid-free Analgesia in Intensive Care Unit

ICU patients experience moderate to severe pain. Studies and guidelines point out the benefits of multimodal analgesia on pain control, opioid spare and on lowering its adverse effects. However, no recommendation about drugs or protocol has been formulated. In our study, investigators studied the feasibility and the impact on Remifentanil spare of a standardized protocol using multimodal analgesia (Paracetamol, Nefopam, Tramadol, Ketamine, Remifentanil) compared to the standard-of-care strategy using Paracetamol and Remifentanil. The investigators conducted a prospective, ''proof of concept'', randomized, double-blind, parallel group, placebo-controlled trial. The investigators studied multimodal analgesia versus standard-of-care in ICU patients requiring sedation-analgesia for invasive mechanical ventilation.The investigators hypothesized that Remifentanil consumption decrease by 15% with the use of a standardized multimodal analgesia strategy

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

Remy WIDEHEM

Nîmes, Gard, 30029, France

About this study

ICU patients requiring sedation-analgesia for mechanical ventilation for at least 48 hours are randomized in 2 parallel groups : control arm using ''standard of care'' analgesia (Paracetamol and Remifentanil), and interventional arm using multimodal analgesia at different level according to pain accessed by BPS (Step 1 : Paracetamol, Nefopam, Tramadol, Step 2 : Ketamine, Step 3 : Remifentanil). Sedation drugs are standard of care (Propofol and Midazolam if Propofol isn't enough) to obtain prescribed sedation accessed by RASS. Double-bling is kept for 72 hours until the primary outcome is obtained.

The investigators hypothesize a 15% reduction of Remifentanil consumption in the interventional group.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patient hospitalized in ICU and requiring sedation-analgesia for mechanical ventilation.
  • Patient undergoing mechanical ventilation for more than 2 hours and less than 24 hours.
  • Informed consent signed by the patient or his trusted person, legal representative, family member, curator or tutor, or emergency consent procedure.
  • Patient affiliated to the French Government Public Health Insurance.
  • Patient over 18 years old.

Exclusion criteria

  • Patient already involved in a trial that might influence our primary endpoint.
  • Patient in exclusion-period determined by another trial or study.
  • Patient who is likely to be requiring less than 48 hours of mechanical ventilation.
  • Patient with contraindication or allergies to at least one of the following medication : paracetamol, nefopam, tramadol, ketamine, remifentanil.
  • Patient with hepatic insufficiency (defined as PT < 50%).
  • Parturient or breast-feeding patient.
  • Patient suffering from moderate to severe Acute Respiratory Distress Syndrome (ARDS), with decreased PaO2/FiO2 ratio under 150mmHg after respiratory optimization (courant volume 6mL/kg and PEEP > 5mbar).
  • Patient requiring curare treatment.
  • Patients with an indication for locoregional analgesia prior to extubation (perineural sealing, epidural analgesia).

Treatment and study plan

OFA multimodal analgesia

Drug

Multimodal opioid free analgesia

standard multimodal analgesia

Drug

Standard remifentanil analgesia

Primary outcomes

  1. Daily remifentanil consumption (after randomisation)

    Time frame: 48th hour after randomisation

    daily consumption of remifentanil between the 24th hour and the 48th hour after randomisation of patients admitted to the ICU and requiring at least 48 hours of mechanical ventilation

Secondary outcomes

  1. Impact of a non-opioid analgesia strategy on morphine savings at D7

    Time frame: Day 28

    Cumulative dose of remifentanil

  2. Impact of an opioid-free analgesia strategy on sedative consumption

    Time frame: Day 28

    Number of lived days free of remifentanil

  3. Impact of an opioid-free analgesia strategy on sedative consumption

    Time frame: Day 28

    Daily consumption of sedative drugs from inclusion to D28

  4. Impact of a non-opioid analgesia strategy on the duration of mechanical ventilation

    Time frame: Day 28

    Number of live days free of mechanical ventilation

  5. Impact of an opioid-free analgesia strategy on norepinephrine

    Time frame: Day 28

    Number of lived days free of norepinephrine

  6. Impact of a non-opioid analgesia strategy on organ failure at D28

    Time frame: Day 28

    SOFA Score (Sepsis-related Organ Failure Assessment)

  7. Impact of a non-opioid analgesia strategy on fluid intake

    Time frame: Day 28

    Daily fuid intake in milliliter

  8. Impact of a non-opioid analgesia strategy on mental confusion

    Time frame: Day 28

    CAM ICU test

  9. Impact of a non-opioid analgesia strategy on the occurrence of morphine-related adverse events

    Time frame: Day 28

    Presence of one or more events of special interest or expected adverse events: constipation, bradycardia, bladder globe, nausea, vomiting, liver disturbance, serotonin syndrome

  10. Impact of a non-opioid analgesia strategy on the incidence of ventilator-associated pneumonia

    Time frame: Day 28

    Presence of pneumonia associated with mechanical ventilation

  11. Impact of a non-opioid analgesia strategy on extubation failure rates

    Time frame: 48 hours after extubation

    extubation failure and cause (reintubation within 48 hours of first extubation)

  12. Impact of a non-opioid analgesia strategy onICU and hospital length of stay

    Time frame: Day 90

    Length of stay in the intensive care unit and in the hospital

  13. Impact of the non-opioid analgesia strategy on vital prognosis at D28 and D90.

    Time frame: Day 90

    Vital status at day 28 and day 90

  14. Impact of a non-opioid analgesia strategy on morphine dependence at D90

    Time frame: Day 90

    Opioid use at D90

Sponsors and collaborators

Lead sponsor

Centre Hospitalier Universitaire de Nīmes

Other

Registry information

Official study title

Opioid-free Analgesia in Intensive Care Unit: a Prospective, Monocentric, Randomized, Double Blind, Feasability Clinical Trial

Acronym: OFICU

Important dates

Study start
2023
Primary completion
2026
Study completion
2026
First posted
Apr 24, 2023
Registry last updated
Jul 1, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.